7.92
Day One Biopharmaceuticals Inc Aktie (DAWN) Neueste Nachrichten
How buybacks impact Day One Biopharmaceuticals Inc. stock valueTrade Performance Summary & Verified High Yield Trade Plans - Newser
Day One to buy Mersana Therapeutics for $25/share upfront - MSN
Day One Biopharmaceuticals, Inc. $DAWN Shares Purchased by Geode Capital Management LLC - MarketBeat
Will Day One Biopharmaceuticals Inc. stock deliver shareholder valueJuly 2025 Patterns & Fast Exit and Entry Strategy Plans - Newser
What drives Day One Biopharmaceuticals Inc stock pricePrice Momentum Alerts & Investor Community Interactions - earlytimes.in
(DAWN) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
DAWN CEO moves Day One shares among Bender family trusts - Stock Titan
Day One Biopharmaceuticals (NASDAQ:DAWN) Trading 8% HigherStill a Buy? - MarketBeat
How Recent Developments Are Shaping the Day One Biopharma Investment Story - Yahoo Finance
HC Wainwright & Co. Reiterates Day One Biopharmaceuticals (DAWN) Buy Recommendation - Nasdaq
DAWN: HC Wainwright & Co. Reaffirms Buy Rating with $25 Target | - GuruFocus
Buy Rating Affirmed for Day One Biopharmaceuticals: Promising FIREFLY-1 Trial Results and Ojemda’s Market Potential - TipRanks
Day One Biopharmaceuticals Announces Three-Year Results from FIREFLY-1 Trial - TradingView
Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting - The Manila Times
[8-K] Day One Biopharmaceuticals, Inc. Reports Material Event | DAWN SEC FilingForm 8-K - Stock Titan
Day One Announces Three Year Follow-Up Data From OJEMDA™ - GlobeNewswire
Will Hindalco Industries Limited Stock Benefit From Industry Trends in YEARBearish Engulfing Patterns & Minimize Portfolio Damage with Warnings - earlytimes.in
Is Day One Biopharmaceuticals Inc a good long term investmentRisk Adjusted Returns & High Profit Market Tips - earlytimes.in
Day One Biopharmaceuticals unveils promising Phase 2 trial data - Traders Union
Will Day One Biopharmaceuticals Inc. stock maintain momentum in 2025Trade Analysis Report & Verified Chart Pattern Trade Signals - newser.com
Can Day One Biopharmaceuticals Inc. stock maintain growth trajectoryWeekly Stock Summary & Technical Confirmation Trade Alerts - newser.com
Wall Street Analysts Believe Day One Biopharmaceuticals (DAWN) Could Rally 161.36%: Here's is How to Trade - MSN
Can Day One Biopharmaceuticals Inc. stock deliver consistent earnings growthJuly 2025 Breakouts & Real-Time Market Trend Scan - newser.com
Will Day One Biopharmaceuticals Inc. stock recover faster than peersAnalyst Upgrade & Safe Entry Zone Tips - newser.com
Day One Biopharmaceuticals, Inc.Common Stock (NQ: DAWN - Markets Financial Content
Day one biopharma gen counsel sells $38k in shares By Investing.com - Investing.com South Africa
Can Day One Biopharmaceuticals Inc. rally from current levelsQuarterly Trade Review & Free Low Drawdown Momentum Trade Ideas - newser.com
Key resistance and support levels for Day One Biopharmaceuticals Inc.Index Update & Safe Swing Trade Setup Alerts - newser.com
Day One Biopharmaceuticals Inc. stock volume spike explainedTrade Signal Summary & Weekly High Conviction Trade Ideas - newser.com
Day one biopharma gen counsel sells $38k in shares - Investing.com
[Form 4] Day One Biopharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Day One Biopharmaceuticals Executives Sell Shares to Cover Tax Liabilities - TradingView
COO York II Acquires 12,813 Of Day One Biopharmaceuticals Inc [DAWN] - TradingView
Day One Biopharmaceuticals CEO Jeremy Bender Sells Shares - TradingView
What Fibonacci levels say about Day One Biopharmaceuticals Inc. reboundTake Profit & Daily Profit Focused Stock Screening - newser.com
Key deals this week: Merck, Day One Biopharmaceutical, ABN AMRO, Revvity, Centerspace and more - MSN
Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):